Tau imaging of patients with different kinds of dementia and a peptide microarray that detects antibody patterns in Alzheimer's disease blood samples were among the highlights of the American Academy of Neurology annual meeting, held April 26-May 3 in Philadelphia. Alzforum coverage includes the latest on the newly approved amyloid tracer florbetaben, and a snapshot of this year’s Potamkin Prize winner.
Marek-Marsel Mesulam received the prestigious award for his research on primary progressive aphasia, a language disorder that can affect people with Alzheimer’s or frontotemporal dementia.
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
Tau and amyloid PET tracers demonstrate potential to sharpen the diagnosis of Alzheimer’s disease and frontotemporal dementias.
Will an antibody signature make for a new Alzheimer’s diagnostic?